Adherence in Adolescents and Children Treated on Quetiapine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-08-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study aimed to describe the adherence in a population of adolescents and children treated on quetiapine from a first psychotic episode whose more important secondary objective is to identify possible predictive factors influencing the adherence to treatment with Quetiapine

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psychosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Psychosis adolescents adherence quetiapine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least one psychotic symptom (delusions or hallucinations) before age 18.
* Start of treatment in a maximum period of 2 years after the onset of first psychotic symptom
* Written informed consent by parents or guardians and patients.

Exclusion Criteria

* Pregnancy or lactancy
* High risk of aggression or suicidal behaviour
* Alcohol dependence

Minimum Eligible Age

7 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca Pharmaceuticals Spain S.A

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NES-SER-2006/1

Identifier Type: -

Identifier Source: org_study_id